Back

Akums Drugs & Pharmaceuticals Ltd.

IPO Details · GMP · Subscription · Financials

✅ Listed NSE & BSE Mainboard Live Chart
Issue Price
₹679
Per Share
GMP
NIL
Grey Market
Est. Listing
₹679
Expected Price
Min. Application
₹29,876
2 lots × 22 shares
IPO Issue Details
Issue Price / Price Band₹679 per share (Fixed Price)
Face Value₹2 Per Share
Lot Size22 Shares per Lot
Total Issue Size2,73,68,143 shares (aggregating up to ₹1,856.74 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenTue, 30 Jul 2024
Subscription CloseThu, 01 Aug 2024
Anchor AllotmentMon, 29 Jul 2024
Basis of AllotmentFri, 02 Aug 2024
Initiation of RefundsMon, 05 Aug 2024
Credit of Shares to DematMon, 05 Aug 2024
Listing DateTue, 06 Aug 2024
UPI Mandate Deadline2024-08-01
Application & Investment Details
Retail — Min (1 Lots)₹14,938 — 22 shares
Retail — Max (13 Lots)₹194,194 (13 Lots)
HNI — Min (14 Lots)₹2,09,132 — 308 shares
Pre-IPO Promoter Holding14,73,56,280 shares
Post-IPO Promoter Holding15,73,71,007 shares
Fresh Issue Shares1,00,37,708 shares (aggregating up to ₹680.99 Cr)
Offer for Sale Shares1,73,30,435 shares of ₹2 (aggregating up to ₹1,175.75 Cr)
About Akums Drugs & Pharmaceuticals Ltd.

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few.The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023).The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF).As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.

Objects of the Issue

Akums Drugs & Pharmaceuticals Ltd. proposes to utilise the net proceeds from the Issue for the following objects:

1
Repayment/ prepayment of indebtedness of the company and its Subsidiaries;
2
Funding incremental working capital requirements of the company;
3
Pursuing inorganic growth initiatives through acquisitions; and
4
General corporate purposes.
Shareholding & Lock-in
Pre-IPO Promoter Holding 14,73,56,280 shares
Post-IPO Promoter Holding 15,73,71,007 shares
Lock-in Period (30%)September 1, 2024
Lock-in Period (50%)October 31, 2024
Check AllotmentCheck Status →
Akums Drugs & Pharmaceuticals Ltd. — Live Price LIVE
₹679.00
INR · BSE
Fetching live data…
VS Issue Price
OPEN
HIGH
LOW
MKT CAP
P/E
52W HIGH
52W LOW
VOLUME
DIVIDEND
DIV YIELD
Loading chart…
Chart Not Available
Akums Drugs & Pharmaceuticals Ltd. is not yet listed on Yahoo Finance or has a different ticker symbol.
Try again after listing stabilises (2-3 trading days).
Issue ₹679.00 Live Price
Quick Facts
GMP Signal ⚪ No GMP
StatusListed
Issue Price₹679
GMPNIL
Est. Listing₹679
Lot Size22 shares
Min Amount₹29,876
Listing Date06 Aug 2024
Disclaimer: GMP is unofficial and unregulated. It does not guarantee actual listing price.
Listing Performance
Issue Price₹679
Listing Date06 Aug 2024
Listing Price
Listing Gain/Loss—%
52-Week High
52-Week Low
Issue Structure & Reservation
Category Shares Offered % Issue Amount (₹ Cr)* Subscription
TOTAL 27,368,151 100.00% ₹1,858.30 Cr
* Based on ₹679.00 (upper price band)
Lot Size & Investment Details
Lot Size
22
Shares
Issue Price
₹679.00
Per Share
Min Investment
₹14,938
1 Lot
Category Lots Shares Amount (₹)
Retail (Min) 1 22 ₹14,938
Retail (Max) 13 286 ₹194,194
sNII (Min) 14 308 ₹209,132
bNII (Min) 68 1,496 ₹1,015,784
Company Financials — Restated Consolidated (Amount In Crore)
Particulars31 Mar 202431 Mar 202331 Mar 2022
Revenue from Operations 4212.21 3700.93 3694.52
EBITDA N/A N/A N/A
Profit After Tax (PAT) 0.79 97.82 -250.87
Net Worth 709.50 717.19 621.98
Total Assets 3516.37 3266.53 3069.05
Reserves & Surplus 861.01 868.70 787.79
Total Borrowings 491.56 536.97 357.95
Key Ratios & Valuation
Issue Price ₹679
Face Value ₹2 Per Share
P/BV 13.69
RoE 0.11%
RoCE 3.37%
RoNW -0.57
PAT Margin (%) 0.02%
EBITDA Margin (%) N/A
Debt / Equity 0.69
Company Details
Company
Akums Drugs & Pharmaceuticals Ltd.
Exchange
NSE & BSE
IPO Type
Mainboard IPO
Issue Type
Bookbuilding IPO
Face Value
₹2 Per Share
Script Code
N/A
Address
304, Mohan Place, LSC Saraswati Vihar, Delhi - 110 034 Delhi, New Delhi
Book Running Lead Managers
ICICI Securities Ltd.
Book Running Lead Manager (BRLM)
Axis Bank Ltd.
Book Running Lead Manager (BRLM)
Citigroup Global Markets India Pvt.Ltd.
Book Running Lead Manager (BRLM)
Ambit Pvt.Ltd.
Book Running Lead Manager (BRLM)